Science & Health
0 Comments

India Develops Affordable Vaccine Against Cervical Cancer

For the first time in India, a domestically-made vaccine that provides protection against cervical cancer—the second-most common type of cancer afflicting women in the country—will be accessible to the majority of the population, including the poorest, according to leading healthcare professionals.

The vaccine, Cervavac, is produced by The Serum Institute of India (SII), the world’s largest vaccine manufacturer. The vaccine shot is expected to launch by December this year, SII chief executive Adar Poonawalla said in a statement Tuesday.

“Cervavac will make India self-sufficient in controlling female mortality caused by cervical cancer. The government of India will induct it in the national [vaccination] program in a few months,” Poonawalla said.

The vaccine protects against the Human Papilloma Virus, the main cause of cervical cancer and a potential cause of other cancers. SSI says it will be accessible to both men and women at a price range of 200 to 400 rupees—about $2.50 to $5.

Dr. Smita Joshi, leader of the SII’s HPV vaccine study, said “The vaccine will be chiefly beneficial for girls aged 9 to 15 or women who are not yet sexually active.

“If we vaccinate adolescent girls now, its effect on reducing the cancer burden in the country will be seen within three to four decades,” she said.

According to Joshi, the effectiveness of the vaccine is lower among adult women, who will require cervical cancer screenings—preferably with an HPV test—followed by appropriate management for those who test positive for sexually transmitted HPV.

Dr. Mayoukh Kumar Chakraborty, assistant professor of gynecology and obstetrics at Kolkata’s KPC Medical College & Hospital, said even though three highly effective foreign-manufactured HPV vaccines are already available in India, the cheapest of them is priced around $35 per dose.

“So, HPV vaccination was not included in the national immunization program following its introduction in 2008,” he said.

In a statement, SII said it is offering Cervavac at a lower price because of the company’s “philanthropic philosophy” and to protect under-privileged children all over the world.

According to India’s Science and Technology Ministry, cervical cancer kills about 75,000 Indian women per year.

Science and Technology Minister Dr. Jitendra Singh said that the COVID-19 pandemic has sparked awareness regarding preventative healthcare and India can now afford to start developing its own vaccines.

“Therefore, vaccination against HPV is the most promising initiative in the quest to prevent cervical cancer,” he said.

Joshi, who also leads the World Health Organization’s HPV vaccine study at Jehangir Clinical Development Center in the city of Pune, said: “The awareness about cervical cancer prevention in India, which includes vaccination and cervical cancer screening, is dismally low.”

There are many misconceptions regarding the disease, even among the educated population and healthcare providers, she said.

“It is advised that adolescent girls get HPV vaccinations, and that women between the ages of 30 to 49 get cervical cancer screenings, even if they have no symptoms,” she added.

Chakraborty, the gynecologist, said the upcoming Indian vaccine is expected to be effective.

“The country’s drug regulatory authority examined the data of Cervavac’s immunogenicity trials conducted at 13 centers across India and approved the vaccine in July. It is expected to generate a robust response in 100% of the vaccine recipients, according to the third phase of the trials,” he said.

Joshi added: “Through this initiative, the goal of eliminating cervical cancer from the country may be attainable.”

Bollywood actor Manisha Koirala, who has been an ovarian cancer survivor for ten years, thanked the Ministry of Science and Technology at the event announcing the impending launch of Cervavac.

“It is a great day for women in India and the world over, as there is life beyond cancer,” she said.

0
Science & Health
0 Comments

Angelina Jolie Makes Surprise Visit to Flood-hit Pakistan

Hollywood actress and U.N. humanitarian Angelina Jolie made a surprise visit to one of the worst flood-hit areas in southern Pakistan on Tuesday, officials said, as the death toll from months-long deluges rose to 1,559.

TV footage showed Jolie arriving at an airport in Karachi, the capital of southern Sindh province, where floods since mid-June have killed 692 people, damaged hundreds of thousands of homes and left half a million people homeless.

Later, she visited some of the flood-affected areas, according to local media.

According to the IRC, a prominent international aid group, Jolie is visiting Pakistan to support communities affected by the devastating floods.

There was no comment from the government about Jolie’s visit to Dadu, one of the worst-hit districts where waterborne diseases have also caused nearly 300 deaths since July. Currently, doctors are trying to contain the outbreak of waterborne diseases among flood survivors.

The visit comes as Pakistan’s Prime Minister Shahbaz Sharif is in New York for the 77th session of the U.N. General Assembly. In his speech, Sharif will highlight the damages caused by climate-change induced floods in the impoverished country.

Pakistan says the floods have caused $30 billion in damages to the country’s economy.

0
Science & Health
0 Comments

Uganda Confirms Ebola Outbreak After Man Dies From Virus

Officials in Uganda have confirmed an outbreak of the deadly Ebola virus. The country’s Ministry of Health says a young man died of the virus in central Uganda Monday, and several of his relatives who died earlier this month are also suspected to have had Ebola. The government has sent a rapid response team to the area to investigate. 

Uganda’s Ministry of Health officials say the suspected Ebola case was identified Saturday in a village in the central Mubende district.  

The ministry’s permanent secretary, Dr. Diana Atwine, says a 24-year-old man was admitted to a hospital for pneumonia and diarrhea.  

But his symptoms also included those of the deadly virus — a dry cough, high fever, convulsions, blood-stained vomit and bleeding in the eyes. 

Speaking at a press conference Tuesday, Atwine said the clinical team and the Uganda Virus Research Institute conducted tests for Ebola.

“The results were released yesterday evening and they confirmed Ebola, the Sudan strain,” she said. “Unfortunately, that morning of 19th, the patient who had been confirmed with Ebola passed on.”

Atwine said six of the man’s relatives who died earlier this month — three adults and three children from the same family — also may have had Ebola. 

The World Health Organization’s Uganda office says there are eight more people with suspected cases that are receiving care at a health facility.  

Uganda’s health ministry has yet to identify the source of the infection but suspects wildlife to human contact.

A rapid response team was sent to Mubende to investigate, put in place control measures, and use rapid testing on contacts in the community. 

But the World Health Organization says vaccinating those who were in contact with the infected or someone linked to them, known as ring vaccination, will not be possible.

WHO-Uganda’s head of disease prevention and control, Dr. Bayo Fatunmbi, told the briefing there is currently no effective vaccine available for the Sudan strain of Ebola.

“The ring vaccination that worked with [the] Zaire virus, will not be useful for this particular Sudan strain,” he said. “But there’s another type of vaccine, Johnson and Johnson, that is being tested currently [to see] whether it will be useful for this particular strain.”

The WHO says ring vaccination has been highly effective in controlling the spread of the Zaire strain in recent Ebola outbreaks in the Democratic Republic of Congo.

The WHO says Uganda’s last Ebola outbreak in 2019 was the Zaire strain. Uganda last reported the relatively rare Sudan strain outbreak in 2012.  

The U.S. Centers for Disease Control and Prevention is helping Uganda deal with this latest outbreak.  

Amy Boore, the CDC’s Global Health Protection program director, told reporters they were prepared to assist the Uganda Virus Research Institute.

“CDC headquarters is already in communication with UVRI (Uganda Virus Research Institute) and is already helping them develop plans for how they will continue to test and expand testing and have all the support they need during this,” she said.

Ebola is spread through bodily fluids and causes a hemorrhagic fever that kills up to 90% of those infected.  The WHO says case fatality rates of the Sudan virus have varied from 41% to 100% in past outbreaks.

The Sudan strain of Ebola, discovered in Sudan in 1976, is less common than the Zaire strain that was found that same year.

The Zaire strain of Ebola was named after the country and river where it was found, the Ebola River in the former Democratic Republic of Congo (DRC).  

The DRC’s name was changed to Zaire in 1971 then changed back to Democratic Republic of Congo in 1997.  

Health authorities in the neighboring DRC in late August declared a resurgence of Ebola after confirming a case in the country’s eastern North Kivu province.  

It was the fifteenth resurgent outbreak recorded in the DRC.

0